US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japanmarketing2021-02-26T19:11:02+00:00November 29th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinibmarketing2021-02-26T19:11:39+00:00November 19th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japanmarketing2021-02-26T19:11:48+00:00November 19th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)marketing2021-02-26T19:12:02+00:00September 27th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panelsmarketing2021-02-26T19:12:15+00:00May 9th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutationsmarketing2021-02-26T19:12:23+00:00May 8th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
